J&J is predicting 2026 revenues will be between $99.5 billion and $100.5 billion, up from just over $94 billion in 2025.

Roche's Gazyvaro, a drug that can restore kidney function in people living with lupus nephritis, has been cleared for use by ...

Amazon has become the latest tech company to introduce an AI-powered assistant that is designed to provide health guidance ...

The WHO has been working over the past year to try to get the Trump administration to change course, and Director General ...

GSK gets an entry in the list with Exdensur (depemokimab), a twice-yearly injectable IL-5 inhibitor for severe asthma, which ...

Laboratory services leader adds pharma veteran to board. Lab services giant LabCorp appointed Novartis US President Victor ...

The intention with STEM AI is to go beyond KPIs to deliver deeper insights into what truly drives performance and outcomes ...

In a wide-ranging sit down during JP Morgan Week in San Francisco, Astellas' chief strategy officer Adam Pearson walked ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene ...

Shares in ImmunityBio rose sharply after the company said it has agreed a path with the FDA that will allow it to refile for ...

Tickets are on sale for the 40th anniversary of the PM Awards! Book now and join us on Friday 20 th March 2026 at the JW ...

The European Commission has approved Otsuka's Dawnzera for the prevention of recurrent attacks in rare disease hereditary ...